Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2010) 22 P544

ECE2010 Poster Presentations Male reproduction (28 abstracts)

Testosterone replacement therapy isn't always contraindicated after prostate cancer treatment: case report

Rachel Smith , N Karavitaki & John Wass


Department of Endocrinology, OCDEM, Churchill Hospital, Oxford, UK.


We present the case of a 62 year old gentleman who was diagnosed with Acromegaly in 1998.

He commenced testosterone replacement therapy in the form of Sustanon every three weeks in October 2000 following a testosterone level of 6.6 nmol/l.

PSA levels during treatment with Sustanon were: 01/03/01–5.1μg/l.

06/04/01–4.9 μg/l at which point he was referred for a urological opinion.

On the 13/02/02 he underwent prostate biopsies which were benign.

Sustanon was stopped August 2002.

PSA on the 14/11/02 was 5.3 μg/l. More biopsies were taken which showed Gleason 3+3=6 carcinoma stage T1c.

He commenced radical radiotherapy which was completed on the 30/05/03 – total dose of 55Gy in 20 daily fractions.

PSA on the 19/09/03 was 1.0 μg/l with a morning testosterone of 5.2 nmol/l. Therefore he commenced Testogel 25 mg daily in November 2003 with 3 monthly PSA levels.

PSA levels have ranged from 0.6 to 1.0 μg/l up to the present day with no cancer recurrence.

In February 2009 he changed to Tostran 30 mg daily and continues to have ongoing follow-up with the urologist and oncologist.

A literature review was undertaken exploring testosterone replacement therapy following treatment for prostate cancer, and concluded that testosterone therapy can be considered after radical treatment of prostate cancer by prostatectomy.

Conclusion: Testosterone replacement therapy isn’t always contraindicated forever, in patients who have had prostate cancer.

Article tools

My recent searches

No recent searches.